Insmed reports third-quarter 2024 financial results and provides business update

—arikayce® (amikacin liposome inhalation suspension) total revenue of $93.4 million for the third quarter of 2024, reflecting 18% growth over the third quarter of 2023— —nda submission for brensocatib in bronchiectasis remains on track for the fourth quarter of 2024 with potential u.s. launch still expected in mid-2025— —expanded u.s. sales force is now fully deployed; focusing on bronchiectasis disease-state awareness and supporting the growth of arikayce prior to the anticipated launch of brensocatib— —ends the third quarter with ~$1.5 billion in cash, cash equivalents, and marketable securities— —renegotiates term loan with pharmakon resulting in a lower cost of capital and an additional $150 million in proceeds to be received in the fourth quarter— —reiterates 2024 global arikayce revenue guidance in the range of $340 million to $360 million, reflecting double-digit growth compared to 2023— bridgewater, n.j. , oct. 31, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended september 30, 2024, and provided a business update.
INSM Ratings Summary
INSM Quant Ranking